LeMaitre Q4 sales up 8% organic; EPS $0.25 (-9%); dividend raised 12% to $0.14; $25M buyback authorized

LEMAITRE VASCULAR INC

2022-FY EPS reported $0.93 revenue$161,651,000

Q4 sales $41.0M (+4% reported, +8% organic); net income $5.6M (-9%); EPS $0.25 (-9%).
Gross margin 63.6% vs 65.7% (150 bps FX headwind); op income $7.0M (-16%).
Quarterly dividend raised 12% to $0.14/share, payable March 23 to record March 9.
Board authorized $25M share repurchase program through Feb 21, 2024.
Q1 2023 guidance: sales $42.6-45.0M (mid +11% reported, +13% organic); EPS $0.22-0.27.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LEMAITRE VASCULAR INC reported the quarter ended December 31, 2022 results: revenue $41.0mm, net income $5.6mm, EPS $0.25. Guidance initiated.

Period: the quarter ended December 31, 2022
Revenue: $41.0mm
Net income: $5.6mm
EPS: $0.25
Guidance: initiated
Result: preliminary results

Exact text from the filing

implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance. Q4 2022 Financial Results ● Sales $41.0mm, +4% (+8% organic) vs. Q4 2021 ● Op. income $7.0mm, -16% ● Op. margin 17% ● Net income $5.6mm, -9% ● Earnings per diluted share $0.25, -9% ●

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

LEMAITRE VASCULAR INC filing history →

Source: SEC EDGAR

accession 0001437749-23-004378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.